Navigation Links
Andre Marion Joins Microchip Biotechnologies' Board of Directors
Date:5/7/2009

DUBLIN, Calif., May 7 /PRNewswire/ -- Microchip Biotechnologies, a private company developing the Apollo next-generation fluidics platform for life sciences, announced today that Andre F. Marion has accepted a board position to its Board of Directors, effective immediately. Mr. Marion was former CEO of Applied Biosystems and today serves on the boards of several venture capital backed companies.

"Andre Marion brings an immense depth of global commercial and operational experience in the life science tools market to Microchip Biotechnologies' Board of Directors. His leadership of Applied Biosystems and experience on other Boards will greatly assist the stewardship of our company," said Dr. Stevan Jovanovich, President and CEO of Microchip Biotechnologies.

"I believe that the simplicity, flexibility and potential for low cost manufacturing offered by Microchip Biotechnologies' Apollo platform are particularly well suited for the design of integrated systems that can accelerate the collection, preparation and analysis of biological samples," said Mr. Marion. "A wide variety of applications in life science research, diagnostics, and environmental fields, that require robustness and reliability, are obvious candidates for the platform."

Andre F. Marion was a co-founder of Applied Biosystems; Applied Biosystems was acquired by Invitrogen in 2008 to form Life Technologies. At Applied Biosystems Mr. Marion held a series of pivotal positions. He initially held the post of Vice President of Engineering in 1981 and became Chief Operating Officer in 1983. In 1986 Mr. Marion was promoted to President and Chief Executive Officer of Applied Biosystems and also held the position of Chairman of the Board from 1987 until 1993 when Applied Biosystems merged with Perkin Elmer. Andre F. Marion retired from Perkin Elmer Corporation as President of the Applied Biosystems Division in 1993. Prior to founding Applied Biosystems, he held various Research and Development managerial positions at Hewlett-Packard.

As a native of France, Mr. Andre F. Marion holds an engineering degree from the French Ecole Nationale Superieures d'Ingenieurs Arts et Metiers in both mechanical and electronic engineering.

About Microchip Biotechnologies

Microchip Biotechnologies, Inc., (MBI), is a privately-held company located in Dublin, California. The company is developing the Apollo next-generation fluidics platform for life sciences, applied sciences, and diagnostics markets. The Apollo platform integrates advanced microfluidic sample preparation, and analytical capabilities, to produce sample-to-answer performance for DNA sequencing, biodefense, DNA-based forensics and human identity (HID), and molecular diagnostics applications. The platform incorporates MBI's proprietary BeadStorm(TM) bead-based sample preparation devices and 'Microscale On-Chip Valve' (MOVe(TM)) valves, pumps, and routers on microchips. More details about MBI, its technologies and products can be found at: www.microchipbiotech.com


'/>"/>
SOURCE Microchip Biotechnologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Veridiam Appoints Andrew Gale as Chief Executive Officer
2. Andrew Chisholm Appointed Vice President, Sales and Corporate Accounts at Accumetrics
3. Algeta Appoints Andrew Kay as President and Chief Executive Officer
4. Cyntellect Appoints Former BD Biosciences Executive Andre Lubarsky as Director of Sales - North America
5. [video] Ronald Andrews, CEO of Clarient, Inc. Discusses Agreement With University of Pennsylvania School of Medicine on WallSt.nets 3-Minute Press Show
6. Warner Chilcott Reports the Death of Its Director James Andress
7. 5AM Ventures Announces Expansion of Investment Team: Names Richard Ulevitch Venture Partner; Promotes Kevin Forrest and Andrew McMillan to Principal
8. Clarient CEO Ron Andrews to Participate in OneMedPlace Emerging Healthcare Technologies Finance Forum
9. MacAndrews & Forbes Names Barry F. Schwartz as Executive Vice Chairman
10. Genstructs Andrea Matthews Selected for Mass High Techs People to Watch Under 30
11. Vical Names Andrew de Guttadauro Vice President, Corporate Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and CEO of ... Club. The event entitled “Stem Cells and Their Regenerative Powers,” was ... Dr. Harman, DVM, MPVM was joined by two human doctors: Peter B. Hanson, M.D., ...
(Date:10/10/2017)... ... October 10, 2017 , ... USDM Life Sciences , ... life sciences and healthcare industries, announces a presentation by Subbu Viswanathan and Jennifer ... “Automating GxP Validation for Agile Cloud Platforms,” will present a revolutionary approach to ...
(Date:10/9/2017)... ... October 09, 2017 , ... The award-winning American Farmer television series will ... American Farmer airs Tuesdays at 8:30aET on RFD-TV. , With global population estimates ... of how to continue to feed a growing nation. At the same time, many ...
(Date:10/9/2017)... Antonio, Texas (PRWEB) , ... ... ... new study published on October 5, 2017, in the medical journal, Epilepsia, ... equivalence with the gold standard, video EEG, in detecting generalized tonic-clonic seizures ...
Breaking Biology Technology:
(Date:4/13/2017)... -- According to a new market research report "Consumer IAM ... and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - Global ... grow from USD 14.30 Billion in 2017 to USD 31.75 Billion by ... ... MarketsandMarkets Logo ...
(Date:4/6/2017)... -- Forecasts by Product Type (EAC), Biometrics, ... (Transportation & Logistics, Government & Public Sector, Utilities / ... Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality ... looking for a definitive report on the $27.9bn Access ... ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
Breaking Biology News(10 mins):